低级别浆液性卵巢癌中的RAS-MEK-ERK通路
低级别浆液性卵巢癌(LGSC)常伴浆液性交界性肿瘤,多见于较年轻患者且对铂类化疗相对不敏感。基因组研究显示其频繁存在KRAS、NRAS、BRAF等RAS-MEK-ERK通路突变;一项3期试验中MEK抑制剂曲美替尼治疗复发性LGSC较化疗、激素治疗等其他方案改善临床结局,但比美替尼等部分MEK抑制剂获益有限,RAS通路突变与疗效并不总相关。
要点
- LGSC常伴浆液性交界性肿瘤,KRAS突变率高达54%(主要为非G12C突变)。
- 3期试验中曲美替尼治疗复发性LGSC较化疗、激素治疗等其他方案改善临床结局。
- RAS通路突变与MEK抑制剂疗效并不总相关,需进一步临床与转化研究。
核心结论
- RAS-MEK-ERK通路突变是LGSC的重要治疗靶点,曲美替尼在3期试验中较其他方案改善复发性LGSC的临床结局。
- 部分MEK抑制剂(如比美替尼)获益有限,且RAS通路突变并不总与疗效增加相关,需进一步临床与转化研究。
- avutometinib联合defactinib已于2025年获美国食品药品监督管理局(FDA)加速批准。
研究设计与样本
- 综述,汇总LGSC中RAS-MEK-ERK通路突变的基因组学研究及MEK抑制剂、新型RAS通路靶向药物的临床试验证据。
主要发现
- LGSC存在KRAS(高达54%,主要为非G12C突变)、NRAS和BRAF突变。
- 3期试验中,MEK抑制剂曲美替尼治疗复发性LGSC较化疗、激素治疗等其他治疗方案改善临床结局。
- 其他MEK抑制剂也显示对LGSC有效,部分研究显示携带KRAS突变的肿瘤患者缓解率更高。
- 部分MEK抑制剂试验(如比美替尼)显示获益较有限,RAS通路突变并不总与疗效增加相关。
- avutometinib联合FAK抑制剂defactinib已于2025年获FDA加速批准。
关键数值与推荐
- LGSC中KRAS突变率高达54%,主要为非G12C突变。
- 正在评估的MEK抑制剂联合方案包括联合PARP、AKT、PI3K、CDK4/6或BCL2/BCL-XL抑制剂。
- 正在评估的新型KRAS抑制剂包括KRAS G12C或G12D抑制剂及pan-RAS抑制剂(如RAS(ON)抑制剂RMC-6236)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 部分MEK抑制剂试验(如比美替尼)显示获益较有限。
- RAS通路突变并不总与疗效增加相关。
- 需进一步开展RAS-MEK-ERK通路靶向治疗的临床与转化研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Low-grade serous ovarian cancer (LGSC) is an uncommon subtype of epithelial ovarian cancer, often arising in association with serous borderline tumors (SBT). Compared to high-grade serous ovarian cancers, LGSCs often occur in younger patients and are relatively insensitive to platinum-based chemotherapy, though some patients with LGSC can benefit from hormonal therapies. Genomic studies have demonstrated that SBT and LGSC frequently harbor mutations in members of the RAS-MEK-ERK pathway, which can be targeted therapeutically. LGSC harbor mutations in KRAS (up to 54 %, primarily non-G12C mutations), NRAS, and BRAF. Treatment of recurrent LGSC with the MEK inhibitor trametinib demonstrated improved clinical outcomes relative to other treatment options (chemotherapy, hormonal therapy) in a phase 3 trial. Other MEK inhibitors have also shown efficacy in LGSC, with some studies demonstrating higher response rates in patients whose tumors harbor KRAS mutations. However, some trials of MEK inhibitors showed more limited benefit (e.g. binimetinib), and RAS pathway mutations do not always correlate with increased efficacy, highlighting the need for further clinical and translational research in RAS-MEK-ERK pathway targeted therapeutics. Current clinical trials are evaluating MEK inhibitor combinations such as MEK inhibitors plus inhibitors of poly (ADP-ribose) polymerase (PARP), AKT, PI3K, CDK4/6, or BCL2/BCL-XL. Novel approaches to targeting the RAS-MEK-ERK pathway include the RAF/MEK clamp avutometinib, which has been evaluated in combination with the FAK inhibitor defactinib, and this combination received United States Food and Drug Administration (FDA) accelerated approval in 2025. Multiple newly developed inhibitors of KRAS, including KRAS G12C or G12D inhibitors, as well as pan-RAS inhibitors, including RAS (ON) inhibitors such as RMC-6236, are being evaluated in solid tumors. These emerging strategies for inhibiting RAS-MEK-ERK pathway activity may offer new treatment options for patients with LGSC.
引用
- Stover EH, Lee EK, Shapiro GI, et al. The RAS-MEK-ERK pathway in low-grade serous ovarian cancer. Gynecol Oncol. 2025. PMID: 40680327. doi:10.1016/j.ygyno.2025.06.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。